Theralase TechnologiesTLTFF +1.22%46 PB Ratio is 33.30 as of Jun. 27, 2026, which is 68% above its 10-year median of 19.86. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Theralase Technologies ranks worse than 97.97% on this metric.
The historical rank and industry rank for Theralase Technologies's PB Ratio or its related term are showing as below:
TLTFF'
s PB Ratio Range Over the Past 10 Years
Min: 2.39 Med: 19.86 Max: 86.25
Current: 33.57
During the past 13 years, Theralase Technologies's highest PB Ratio was 86.25. The lowest was 2.39. And the median was 19.86.
TLTFF's PB Ratio is ranked worse than 97.97% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs TLTFF: 33.57
During the past 12 months, Theralase Technologies's average Book Value Per Share Growth Rate was 75.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -20.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -31.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -16.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Theralase Technologies was 194.30% per year. The lowest was -50.90% per year. And the median was 4.20% per year.
Back to Basics: PB Ratio
Theralase Technologies (OTCPK:TLTFF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Theralase Technologies (TLTFF) has a PB Ratio of 33.30 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Theralase Technologies and its competitors. This is 68% above median its historical median of 19.86. Over the past decade, Theralase Technologies' PB Ratio has ranged from 2.39 to 86.25. According to the industry distribution chart, Theralase Technologies ranks #772 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 98%.
Is Theralase Technologies' PB Ratio too high?
Theralase Technologies' current PB Ratio of 33.30 is 68% above median its 10-year median of 19.86. Over the past 10 years, this metric has ranged from a low of 2.39 to a high of 86.25. The Medical Devices & Instruments industry median PB Ratio is 2.02. Theralase Technologies' value of 33.30 is 1548.5% above this industry median. Based on the distribution chart, Theralase Technologies ranks #772 out of 788 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #772 out of 788 companies for PB Ratio. This places Theralase Technologies in the lower half of its industry. The industry median PB Ratio is 2.02. Theralase Technologies' value of 33.30 is 1548.5% above this benchmark. Historically, Theralase Technologies' own PB Ratio has ranged from 2.39 to 86.25 over the past decade. While the company's 10-year median is 19.86 vs. the industry median of 2.02, Theralase Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current PB Ratio of 33.30 is 1548.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current PB Ratio is 33.30, which is 68% above median its own 10-year median of 19.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 28.1% above its estimated fair value. The current PB Ratio is 33.30, which is 68% above median its 10-year median of 19.86 and 1548.5% above the Medical Devices & Instruments industry median of 2.02. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current PB Ratio is 33.30 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.17 is trading 28.1% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Modestly Overvalued.
Key valuation signals for TLTFF:
PB Ratio: 33.30 (68% above median its 10-year median of 19.86)
GF Value™: $0.13 vs. price of $0.17 (28.1% above fair value)
Industry Position: 1548.5% above the Medical Devices & Instruments median (#772 of 788)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
